Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 13/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18892244 | 0.87 | ATR (0.40) | PIK3C3ATRPDCD1CD274MET | |
| SCHEMBL13745998 | 0.80 | BRD4 (0.45) | BRD4MET | |
| SCHEMBL18860623 | 0.79 | ATR (0.45) | PIK3C3ATRBRD4PDCD1CD274 | |
| SCHEMBL18892245 | 0.76 | PIK3C3 (0.46) | PIK3C3ATRPDCD1CD274MET | |
| SCHEMBL18860561 | 0.76 | MAPK1 (0.51) | PIK3C3ATRPDCD1CD274MAPK1 | |
| SCHEMBL25970829 | 0.76 | BRD4 (0.42) | BRD4METMAPK1 | |
| SCHEMBL25970763 | 0.74 | BRD4 (0.45) | PIK3C3BRD4MAPK1 | |
| SCHEMBL25970869 | 0.74 | BRD4 (0.43) | BRD4MAPK1 | |
| SCHEMBL25970660 | 0.74 | BRD4 (0.40) | BRD4METPDE3BPDE3A | |
| SCHEMBL25970793 | 0.73 | BRD4 (0.40) | BRD4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | PIK3C3 127/4885ATR 982/4885BRD4 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.